logo-color
  • HOME
  • About
  • People
  • Process
  • Portfolio
  • News
  • Careers
  • Contact
Mobile Site Logo
  • HOME
  • About
  • People
  • Process
  • Portfolio
  • News
  • Careers
  • Contact

CATEGORY: Press Release

April 8, 2026

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Press Release

January 26, 2026

First Patient Treated in Myra Vision’s U.S. ADAPT Clinical Study for Glaucoma

Press Release

December 1, 2025

Akura Medical, a Shifamed Portfolio Company, Closes $53 Million in Series C Financing

Press Release

September 3, 2025

Laza Medical Achieves First-in-Human Use of Real-Time AI Heart Model for Ultrasound-Guided Cardiac Procedures

Press Release

August 12, 2025

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

Press Release

June 17, 2025

Adona Medical Completes Enrollment in First-in-human Trial for Novel Interatrial Shunt for Patients With Heart Failure

Press Release

May 20, 2025

FDA Grants Atia Vision Approval to begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts

Press Release

March 26, 2025

Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

Press Release

March 3, 2025

Myra Vision Announces Positive Initial Outcomes from its Feasibility Study at the 2025 American Glaucoma Society Meeting

Press Release

February 4, 2025

First patient enrolled in Akura Medical’s US pivotal trial for pulmonary embolism

Press Release

  • « older posts
Link to top of page

© 2026 All Rights Reserved  Privacy Policy

Shifamed, LLC

590 Division Street

Campbell, CA 95008

info@shifamed.com

PHONE: +1 408.560.2500

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}